智通财经APP讯，复星医药(02196)发布公告，近日，上海复星医药(集团)股份有限公司(以下简称“本公司”)控股子公司重庆药友制药有限责任公司就左氧氟沙星注射液(以下简称“该药品”)的药品注册申请获国家药品监督管理局批准。本次获批适应症为用于敏感细菌所引起的下列轻、中、重度感染：(1)医院获得性肺炎;(2)社区获得性肺炎;(3)急性细菌性鼻窦炎;(4)慢性支气管炎的急性细菌性发作;(5)复杂性皮肤及皮肤结构感染;(6)非复杂性皮肤及皮肤软组织感染;(7)慢性细菌性前列腺炎;(8)复杂性尿路感染;(9)急性肾盂肾炎;(10)非复杂性尿路感染;(11)吸入性炭疽 (暴露后)。
该药品为本集团(即本公司及控股子公司/单位，下同)自主研发的化学药品。截至2026年4月，本集团现阶段针对该药品的累计研发投入约为人民币194万元(未经审计)。
根据IQVIACHPA最新数据，2025年，左氧氟沙星注射剂于中国境内(不包括港澳台地区)的销售额约为人民币10.57亿元。
该药品本次获批上市，将进一步丰富本集团产品线。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.